CURVEBEAM AI LIMITED (CVB)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CVB - CURVEBEAM AI LIMITED
FNArena Sector :
Medical Equipment & Devices
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -4.27
Index:
FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : NONE
Debt/EBITDA: -4.27
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$0.135
20 Feb |
0.000 OPEN $0.14 |
0.000 HIGH $0.14 |
22 LOW $0.14 |
| TARGET | |||||
|
|||||
| OTHER COMPANIES IN THE SAME SECTOR | |||
| 4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CYC . EBR . EMV . EYE . FPH . IDX . IME . IMR . IPD . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
| Title | FY22 Actual |
FY23 Actual |
FY24 Forecast |
FY25 Forecast |
|---|---|---|---|---|
| EPS (cps) | xxx | - 15.5 | - 6.7 | xxx |
| DPS (cps) | xxx | 0.0 | 0.0 | xxx |
| EPS Growth | xxx | N/A | N/A | xxx |
| DPS Growth | xxx | N/A | N/A | xxx |
| PE Ratio | xxx | N/A | N/A | xxx |
| Dividend Yield | xxx | N/A | 0.0% | xxx |
| Div Pay Ratio(%) | xxx | N/A | N/A | xxx |
Dividend yield today if purchased 3 years ago: N/A
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
| Title | 2023 | 2024 |
|---|---|---|
| EPS Basic | xxx | -7.9 |
| DPS All | xxx | 0.0 |
| Sales/Revenue | xxx | 6.5 M |
| Book Value Per Share | xxx | 11.8 |
| Net Operating Cash Flow | xxx | -21.9 M |
| Net Profit Margin | xxx | -353.94 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2023 | 2024 |
|---|---|---|
| Return on Capital Employed | xxx | - |
| Return on Invested Capital | xxx | -60.78 % |
| Return on Assets | xxx | -37.05 % |
| Return on Equity | xxx | - |
| Return on Total Capital | xxx | -60.80 % |
| Free Cash Flow ex dividends | xxx | -21.9 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
| Title | 2023 | 2024 |
|---|---|---|
| Short-Term Debt | xxx | 1 M |
| Long Term Debt | xxx | 15 M |
| Total Debt | xxx | 16 M |
| Goodwill - Gross | xxx | 20 M |
| Cash & Equivalents - Generic | xxx | 6 M |
| Price To Book Value | xxx | 1.31 |
Short-Term Debt
Long Term Debt
Total Debt
Goodwill - Gross
Cash & Equivalents - Generic
Price To Book Value
| Title | 2023 | 2024 |
|---|---|---|
| Capex | xxx | 0.3 M |
| Capex % of Sales | xxx | 4.96 % |
| Cost of Goods Sold | xxx | 22 M |
| Selling, General & Admin. Exp & Other | xxx | 9 M |
| Research & Development | xxx | 1 M |
| Investments - Total | xxx | 0 M |
Capex
Capex % of Sales
Cost of Goods Sold
Selling, General & Admin. Exp & Other
Research & Development
Investments - Total
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
EXTRA COVERAGE
Display All Commentary
No. Of Recommendations
Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.
CVB STOCK CHART
FNArena News on CVB
| 1 |
FNArena Corporate Results Monitor – 06-09-2024Sep 06 2024 - Australia |
Latest Medical Equipment & Devices News
| 1 |
Trend Remains Up For Catapult InternationalFeb 18 2025 - Technicals |
| 2 |
ESG Focus: Top ASX Companies, Superbugs & HydrogenFeb 07 2025 - ESG Focus |
| 3 |
ResMed Shakes Off GLP-1 ScareFeb 04 2025 - Australia |
| 4 |
ResMed: Another Positive Quarterly Surprise?Jan 30 2025 - Australia |
| 5 |
The Trend Remains Pro Medicus’ FriendJan 16 2025 - Technicals |
| 6 |
Diagnostic Imaging Radiates OpportunityDec 18 2024 - Small Caps |
| 7 |
ResMed’s Bounce-Back CompleteOct 29 2024 - Australia |
| 8 |
Dr Boreham’s Crucible: Pro MedicusSep 04 2024 - Australia |
| 9 |
Pro Medicus: Don’t Stop Me NowAug 20 2024 - Technicals |
| 10 |
Dr Boreham’s Crucible: BlinklabMay 20 2024 - Small Caps |